Related Experiment Videos
[Calcium antagonists and arterial hypertension]
S Laurent1, E Billaud, C Kreft-Jais
1Service de Pharmacologie, Hôpital Broussais, Paris.
Insights
Calcium channel antagonists (CCAs) are a first-line treatment for hypertension, offering benefits like reduced vascular resistance and left ventricular hypertrophy. Further research aims to improve their 24-hour efficacy and cerebrovascular event prevention.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hypertension Management
Background:
- Calcium channel antagonists (CCAs) are a primary monotherapy for essential hypertension.
- CCAs are recommended by the
Purpose of the Study:
- To review the advantages of CCAs in hypertension treatment.
- To identify challenges and future research directions for CCAs.
Main Methods:
- Literature review of CCAs in hypertension management.
- Analysis of clinical trial data and treatment guidelines.
Main Results:
- CCAs effectively lower blood pressure by reducing peripheral vascular resistance.
- CCAs promote regression of left ventricular hypertrophy and offer coronary vasodilation.
- Antihypertensive efficacy is comparable to other major drug classes and generally well-tolerated.
Conclusions:
- CCAs are a valuable therapeutic option for essential hypertension.
- Future research should focus on enhancing 24-hour antihypertensive efficacy and cerebrovascular event prevention.
- Investigating the impact of CCAs on atherosclerosis development is crucial.
Abstract:
The pharmacological class of calcium channel antagonists (CCA) is, with beta-adrenergic antagonists, diuretics, converting enzyme inhibitors and alpha-adrenergic antagonists, one of the first line monotherapies of essential hypertension, according to the recommendations of the "Fifth Joint National Committee on Detection, Evaluation and Treatment of Hypertension". CCA have several advantages for the treatment of hypertension: the blood pressure lowering effect is due to a reduction of total peripheral vascular resistance, which are primarily abnormally increased in hypertension; the antihypertensive efficacy of CCA is comparable to that of other commonly used antihypertensive drugs; CCA induce a significant regression of left ventricular hypertrophy, a factor of morbidity and mortality which is considered to be independent of the level of mean arterial pressure; CCA have vasodilating properties on the coronary circulation; CCA are generally well tolerated, from both clinical and biological points of view. The challenge for CCA concerns three domains related to the morbidity/mortality of hypertension (coronary and cerebrovascular events) a better antihypertensive efficacy for the whole period of 24 hours, a better prevention of cerebrovascular events and an effect on the development of atherosclerosis.